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Drosophila model: a link to clinical 
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Proteasome inhibitors, e.g. Bortezomib (BTZ) and Carfilzomib (CFZ), have demonstrated clinical 
efficacy against haematological cancers. Interestingly, several adverse effects are less common, 
compared to BTZ, in patients treated with CFZ. As the molecular details of these observations remain 
not well understood we assayed the pathophysiological effects of CFZ vs. BTZ in the Drosophila 
experimental model. Mass Spectrometry analyses showed that neither CFZ nor BTZ are hydrolysed 
in flies’ tissues, while at doses inducing similar inhibition of the rate limiting for protein breakdown 
chymotrypsin-like (CT-L) proteasomal activity, CFZ treatment resulted in less intense increase of 
oxidative stress or activation of antioxidant and proteostatic modules. Also, despite comparable 
cardiotoxicity likely due to disrupted mitochondrial function, CFZ did not affect developmental 
processes, showed minimal neuromuscular defects and reduced to a lesser extent flies’ healthspan. 
Studies in flies, human cancer cell lines and blood cells isolated from Multiple Myeloma patients 
treated with CFZ or BTZ revealed, that the increased BTZ toxicity likely relates to partial co-inhibition 
of the caspase-like (C-L) proteasomal activity Supportively, co-treating flies with CFZ and a C-L 
selective proteasome inhibitor exacerbated CFZ-mediated toxicity. Our findings provide a reasonable 
explanation for the differential adverse effects of CFZ and BTZ in the clinic.
Organisms require efficient surveillance of proteome quality to prevent disruption of proteostasis (homeody-
namics of the proteome). Proteostasis maintenance is achieved by the concerted action of a number of modules 
that constitute the proteostasis network (PN). PN is (among others) composed from the network of molecular 
chaperones, as well as from the autophagy lysosome- (ALP) and the ubiquitin proteasome- (UPP) degradation 
pathways1,2. ALP is mostly involved in the clearance of protein aggregates and damaged organelles3, while UPP 
degrades normal short-lived ubiquitinated proteins and non-repairable unfolded polypeptides1,4. The 26 S pro-
teasome is composed from the 20S core particle (CP) and the 19 S regulatory particles (RP)5. Proteasome pepti-
dase activities are localised in the 20S CP and specifically at the β1, β2 and β5 subunits that bear caspase- (C-L; 
LLE/β1), trypsin- (T-L; LRR/β2) and chymotrypsin- (CT-L; LLVY/β5) like proteolytic activity, respectively6,7. 
Proteome functionality also depends on the transcriptional activity of the NF-E2-related factor 2 (Nrf2) which 
upon increased oxidative or proteotoxic stress stimulates the expression of antioxidant enzymes and proteasomal 
subunits8,9.
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Recent findings indicate that over-activation of the proteostatic modules (e.g. UPP) represents a hallmark 
of advanced tumours; and thus, their inhibition provides a strategy for the development of novel anti-tumour 
therapies10. In line with this notion, proteasome inhibitors, e.g. Bortezomib (BTZ) and Carfilzomib (CFZ) have 
demonstrated clinical efficacy in the treatment of multiple myeloma (MM) and mantle cell lymphoma and are 
under evaluation for the treatment of other malignancies11,12. CFZ is an irreversible tetrapeptide epoxyketone–
based proteasome inhibitor (analogue of Epoxomicin) which has demonstrated a high degree of clinical activity 
in patients with relapsed and/or refractory MM11. On the other hand, BTZ is a slowly reversible boronated pro-
teasome inhibitor also showing significant clinical efficacy against haematological malignancies13,14. Most protea-
some inhibitors (including CFZ and BTZ) were designed to target the CT-L activity since this site seems to be the 
rate limiting for protein breakdown15,16. Nevertheless, at higher concentrations these inhibitors may also inhibit 
the C-L or the T-L sites, or both; notably, the biological roles of C-L and T-L sites and their potential as co-targets 
of antineoplastic agents are not well defined17–19. Furthermore, while the use of proteasome inhibitors in the clinic 
during therapeutic treatment of MM patients is linked with several adverse effects, e.g. peripheral neuropathy, 
fatigue, cardiac failure and/or renal failure11,12, these effects are more enhanced or even almost exclusively seen 
(e.g. peripheral neuropathy) after BTZ treatment20–23; yet, the molecular basis of these intriguing clinical obser-
vations is not well understood.
As we recently reported that administration of BTZ to young Drosophila flies caused disruption of proteo-
stasis, reduced motor function (a phenotype that recapitulates the peripheral neuropathy seen in the clinic) and 
a marked reduction of flies’ lifespan9; we sought to comparatively assay the pathophysiological effects of CFZ 
and BTZ in the fly in vivo experimental model. Drosophila is well-suited to this line of investigation, due to its 
powerful genetics; its similarities in key metabolic and ageing pathways with humans24, the fact that it expresses 
proteasomes that structurally resemble those from mammals25, and also because it comprises a soma-germ line 
demarcation composed of both post-mitotic and mitotic cells. Furthermore, apart from significant similarities in 
organs that perform the equivalent functions of the mammalian heart, lung, kidney, gut, and reproductive tract, 
flies are characterised by a well-developed and complicated neural system26. Moreover, they live for few months 
and thus, drug screening on large cohorts can be completed in a reasonable time27,28.
Herein, we report that under conditions of comparable inhibition of the CT-L proteasome activity in flies’ 
tissues, CFZ treatment resulted (as compared to BTZ) in less intense activation of antioxidant and proteostatic 
modules. Also, despite comparable cardiotoxicity, CFZ did not affect developmental processes, reduced to a lesser 
extent flies’ longevity and showed minimal neuromuscular defects. These findings likely relate to increased spec-
ificity of CFZ (vs. BTZ) for the CT-L proteasome activity.
Results
Under conditions of comparable CT-L inhibition, the CFZ-mediated molecular responses are 
milder compared to those observed after BTZ administration. To comparatively assay the effects 
of CFZ and BTZ (Supplementary Fig. S1A) in flies’ tissues, we focused on the CT-L proteasome activity that 
reportedly is selectively targeted by these inhibitors17,29,30. As we had previously observed that BTZ was effective in 
partially suppressing the CT-L proteasome activity in the range of 1–5 μM9 we initially administered CFZ in flies 
at these concentrations; yet, we found no significant inhibitory effect on the CT-L activity. After screening a wide 
range of CFZ doses we observed that it induced an inhibitory effect on CT-L proteasome activity similar to that 
of 1 and 5 μM of BTZ at concentrations of 50 and 75 μM, respectively (Fig. 1A). We also found that CFZ addition 
in flies’ culture medium did not affect the rate of food consumption (Supplementary Fig. S1B) excluding thus the 
possibility of adverse effects due to caloric restriction.
We then sought to investigate the stability of BTZ and CFZ in flies’ culture medium and also to analyse 
whether drugs are hydrolysed and, if not, which is their concentration in flies’ tissues. Our high resolution 
UPLC-MS analyses showed that both drugs were stable in the culture medium (Supplementary Fig. S2A) and that 
in spite of oral administration, they bypass the gastric barrier and they are not hydrolysed, as they were found in 
flies’ tissues (Supplementary Fig. S2B) at concentrations ranging (depending on the input in the culture medium) 
from 9.1 to 33.8 nM for BTZ and from 61.8 to 75 nM for CFZ (Supplementary Fig. S2C).
By studying the molecular effects of CFZ in young flies’ tissues, we noted that (as BTZ) it induced the accu-
mulation of carbonylated proteins (Fig. 1B1) and Advanced Glycation End-products (AGEs; Fig. 1B2). However, 
CFZ induced milder (compared to BTZ) induction of Reactive Oxygen Species (ROS) (Fig. 1C) and a significantly 
less intense activation of Antioxidant Response genomic Elements (AREs) in a reporter transgenic [(gstD1)-ARE: 
GFP/II] fly line (Fig. 1D). In support, gene expression analyses revealed a milder CFZ-mediated upregulation 
of proteasomal (rpn11, α7, β1, β2, β5), antioxidant (keap1, trxr1) and chaperone (hsp70) genes (Fig. 2A), and 
a less intense activation of lysosomal cathepsins (Fig. 2B). As in the case of BTZ treatment9, the CFZ-mediated 
responses on proteasome subunits upregulation were dependent on cap ‘n’ collar isoform-C (CncC; the Nrf2 
ortholog in flies) transcriptional activity, since they were largely abolished after RNAi-mediated knock down 
(KD) of CncC/Nrf2 (Fig. 2C1). In support, the achieved levels of proteasome inhibition were enhanced under 
conditions of CncC/Nrf2 KD (Fig. 2C2). The CFZ-mediated proteasome subunits upregulation was (as for BTZ9) 
age-dependent, since despite effective suppression of the CT-L activity (Supplementary Fig. S3A1,B1), the protea-
some subunits were not significantly induced in CFZ-treated middle aged (Supplementary Fig. S3A2) or aged flies’ 
tissues (Supplementary Fig. S3B2). Considering that the CncC/Nrf2 antioxidant pathway is deregulated during 
ageing9,31, we hypothesise that the abolishment of proteasome upregulation after pharmacological proteasome 
inhibition in aged flies is likely due to CncC/Nrf2 dysfunction.
Taken together these data indicate that under conditions of comparable CT-L inhibition the (age- and 
CncC/Nrf2-dependent) CFZ-mediated molecular responses are milder compared to those observed after BTZ 
administration.
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CFZ shows superiority over BTZ on toxic effects. We then comparatively analysed the pathophysio-
logical effects of CFZ vs. BTZ. Since a severe (yet, less studied) adverse effect of therapeutic proteasome inhibi-
tion relates to cardiotoxicity21,23 we initially focused on analysing the effects on fly hearts. As shown in Fig. 3A 
prolonged treatment with either CFZ or BTZ caused significant cardiotoxicity, including a reduction of the heart 
beats (Fig. 3A), arrhythmia and (at least in CFZ treated flies) in periods of asystole where heart beating tempo-
rarily ceased (Supplementary Videos S1–S3). As cardiomyocytes are heavily dependent on proper mitochondria 
function32,33, we investigated the effect of CFZ and BTZ treatment on mitochondria of heart tubes isolated from 
transgenic flies bearing a mitoGFP reporter expressed in muscle cells (Gal4MEF2 driver). As shown in Fig. 3B, CLSM 
studies revealed that both proteasome inhibitors caused a significant reduction in mitochondria number and also 
affected the overall morphology of heart tubes indicating that proper proteasome functionality is central to main-
tenance of mitostasis. In line with these findings we observed that treatment with BTZ severely affected mitochon-
drial respiration in adult flies (Supplementary Fig. S4A) and in vivo O2 consumption in larvae (Supplementary 
Figure 1. Under conditions of similar CT-L inhibition, CFZ induced milder, as compared to BTZ, antioxidant 
responses and less intense accumulation of ROS. (A) Relative (%) 20S and 26 S CT-L (LLVY/β5) activity in 
flies treated with the indicated doses of CFZ or BTZ for 7 days. (B) Representative immunoblot analyses of 
somatic tissues samples from young flies treated as in (A); protein samples were probed with antibodies against 
Dinitrophenol (DNP) or AGEs. (C) Relative (%) ROS levels in the somatic tissues of young flies exposed to 
shown doses of CFZ or BTZ for 18 days. (D) Relative (%) green fluorescent protein (GFP) levels in the somatic 
tissues of young transgenic gstD-ARE:GFP reporter flies that were treated with the indicated concentrations of 
CFZ or BTZ for 10 days. Control samples were set to 100%; GAPDH probing (B) was used as reference for total 
protein input. Comparisons were vs. control samples from flies grown in inhibitor-free culture medium. Bars, 
±SD (n ≥ 2). *P < 0.05; **P < 0.01.
www.nature.com/scientificreports/
4SCIeNTIFIC REPORTs |  (2017) 7:17802  | DOI:10.1038/s41598-017-17596-4
Fig. S4B). These effects were further confirmed by Electron Microscopy studies in adult flies muscle tissues where 
we observed that treatment with either BTZ or CFZ resulted in severe disruption of mitochondria structure 
(Supplementary Fig. S4C; upper panels) and reduced mean length of mitochondria (Supplementary Fig. S4C; 
Figure 2. Treatment with CFZ promoted milder (as compared to BTZ) upregulation of antioxidant and 
proteostatic cellular modules. (A) Relative expression levels of the rpn11, α7, β1, β2 and β5 proteasome genes; 
atg8 and atg6 autophagic genes; keap1 and trxr1 antioxidant responses related genes and also of the molecular 
chaperone hsp70 gene in the somatic tissues of young flies exposed to CFZ or BTZ for 24 days. (B) Relative (%) 
activities of lysosomal cathepsins B, L in flies’ somatic tissues after treatment with CFZ or BTZ for 9 (B1) or 24 
(B2) days. (C) Representative immunoblots showing Rpn7, 20S-α, β5 and ubiquitin (Ub) expression levels (C1) 
and relative (%) CT-L (LLVY/β5) and C-L (LLE/β1) activities (C2) in somatic tissues of young transgenic flies 
after knocking down CncC/Nrf2; transgenic flies were fed (or not) with RU486 (to induce transgene expression) 
for 2 days and were then exposed (in the presence -or not- of RU486) to the indicated doses of CFZ or BTZ for 
6 days. GAPDH probing (C1) and rp49 gene (A) expression were used as reference for protein and RNA input, 
respectively. Shown comparisons refer to experimental vs. control samples from flies grown in inhibitor-free 
culture medium. Bars, ±SD (n ≥ 2). *P < 0.05; **P < 0.01.
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lower panels). These features indicate that the reduced mitochondrial numbers in flies’ heart tubes after treatment 
with CFZ or BTZ are likely due to enhanced mitochondrial fission and increased rates of mitophagy.
As BTZ had shown severe toxic effects when administered during early developmental stages of flies9, we 
also investigated the impact of CFZ administration during flies’ development and found that it exerted no 
major toxicity. Specifically, we observed normal eclosion after the administration of either 50 or 75 μM of CFZ 
(Supplementary Fig. S5A). Also, flies that had completed development in the presence of CFZ and were then 
grown in inhibitor-free medium showed no reduced longevity as compared to controls that concluded develop-
ment in physiological culture medium (Supplementary Fig. S5B; see also, Supplementary Table S1).
Another major adverse effect of therapeutic BTZ in MM patients is the development of peripheral neuropa-
thy11. Indeed, our previous studies9 had shown that BTZ administration in adult flies resulted in severe decrease 
of climbing activity, indicating reduced neuromuscular performance that recapitulates peripheral neuropathy 
of BTZ treatment in the clinic; also, treatment of flies with BTZ resulted in significant dose-dependent decrease 
in flies’ longevity9. Interestingly, our comparative studies showed that exposure of flies to 50 μM CFZ exerted no 
Figure 3. Both CFZ and BTZ caused cardiac toxicity; yet, CFZ showed minimal neuromuscular defects 
and reduced to a lesser extent flies’ longevity. (A) Heart beats (mean values) normalised to a 30 sec period; 
increasing doses of CFZ or BTZ (exposure for 14 days) led to reduced rate of heart beats and arrhythmia (see 
also, Supplementary Videos S1–S3). (B) CLSM visualization of isolated heart tubes from young UAS mitoGFP/
Gal4MEF2 reporter flies that were exposed for 14 days to the shown concentrations of CFZ or BTZ; nuclei were 
counterstained with DAPI. (C) Climbing (%) (locomotion performance) activity of middle aged flies that were 
treated with the indicated concentrations of CFZ or BTZ for 24 days. (D) Longevity curves of flies exposed 
to the indicated concentrations of CFZ or BTZ; comparative statistics of the longevity assays are reported in 
Supplementary Table S1. Comparisons were vs. control samples from flies grown in inhibitor-free culture 
medium. Bars, ±SD (n ≥ 2). *P < 0.05; **P < 0.01.
www.nature.com/scientificreports/
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significant effect on their climbing activity (neuromuscular performance) (Fig. 3C) and caused a significantly less 
intense (compared to 1 μM BTZ) reduction in flies’ healthspan and longevity (Fig. 3D).
Overall, under conditions of comparable CT-L inhibition, and despite similar cardiotoxicity likely due to 
mitochondrial dysfunction, CFZ administration in flies results in less severe (compared to BTZ) toxic effects on 
the neuromuscular system, as well as in reduced mortality rates.
The milder degenerative effects of CFZ likely relate to its increased selectivity (compared to 
BTZ) for the CT-L proteasomal activity. Reportedly, BTZ can also inhibit the C-L or the T-L proteasome 
sites9,17–19. Thus, we investigated the CFZ effect on these proteasomal peptidases. At in vitro assays in Drosophila 
tissues cell lysate containing intact proteasomes, CFZ showed increased selectivity (although it also modestly 
inhibited the C-L and T-L activities), as compared to BTZ, against the CT-L activity (Supplementary Fig. S6). In 
these series of experiments, we also found that Epoxomicin (a CFZ analogue) was also selective against the CT-L 
activity (Supplementary Fig. S6).
To investigate the in vivo effects of CFZ (vs. BTZ) on the C-L and T-L proteasomal activities we exposed 
flies to proteasome inhibitors either continuously for 12 days, or for three days followed by prolonged cultur-
ing in inhibitor-free medium; proteasome activities were then measured at several time points as indicated in 
Supplementary Fig. S7. We found that under these experimental conditions and doses, CFZ was increasingly 
selective against the CT-L activity, while BTZ also affected the C-L proteasome activity; notably, for both inhib-
itors, T-L activity seemed to fluctuate in a CT-L and C-L independent pattern (Fig. 4A,B). Furthermore, both 
inhibitors were rather stable in young flies’ tissues, as at day four post-exposure to CFZ or BTZ and culturing in 
inhibitor-free medium, proteasome activities were still suppressed (Fig. 4B). These findings were also verified 
after assaying proteasome activities in dissected head (mostly neuronal tissue with minor contributions from 
fat and muscles) and thorax (mainly muscle tissue and the tracheal system) preparations of CFZ or BTZ treated 
flies (Fig. 4C; note that CFZ and BTZ also inhibited T-L activity in head tissues). These data are additive to our 
UPLC-MS findings (Supplementary Fig. S2) as they indicate that orally administered proteasome inhibitors are 
similarly distributed in the various body parts of young flies.
Given the fact that RNAi-mediated KD of either the β5 (CT-L activity) or the β1 (C-L activity) proteasomal 
subunits was developmentally lethal9, we used the C-L selective inhibitor, NC001 (Supplementary Fig. S8; upper 
panel) in order to study the effects of selective C-L inhibition34 in adult flies pathophysiology. We observed that 
addition of NC001 in fly tissues lysate containing intact proteasomes resulted in selective inhibition (at least at the 
lower concentrations of 0.05–0.1 μM) of the C-L activity (Supplementary Fig. S8; lower panel). NC001 was also 
found to demonstrate (at lower concentrations) increased selectivity against the C-L activity at in vivo (supple-
mentation in flies’ culture medium) assays (Supplementary Fig. S9A). In line with the notion that CT-L is the rate 
limiting proteasome activity for protein breakdown15,16, treatment of flies with NC001 did not significantly affect 
(at 2–4 μM) development (not shown) or cellular ROS levels (Supplementary Fig. S9B) and only marginally upreg-
ulated proteasomal subunits expression (Supplementary Fig. S9C). NC001 increased the mortality rate of flies, 
albeit less intensively as compared to either BTZ or CFZ (Supplementary Fig. S9D). However, co-treatment of 
flies with both CFZ and NC001 increased the mortality rate of CFZ (Supplementary Fig. S9E), further supporting 
the notion that the decreased toxicity of CFZ relates to its increased selectivity for the CT-L proteasome activity.
To get more insights into the distinct pattern of toxicity between CFZ and BTZ, we also assayed the basal levels 
of proteasome and lysosomal cathepsins activities in fly tissues or developmental stages enriched in either mitotic 
(ovaries, larvae) or post-mitotic (adult somatic tissues) cells. Interestingly, we noted that both ovaries and larvae 
express significantly higher basal proteasome activities as compared to adult somatic tissues (Fig. 5A). On the 
contrary, adult somatic tissues are characterised by elevated (vs. ovaries or larvae) lysosomal cathepsin activities 
(Fig. 5B). Thus, it is anticipated that mitotic cells (including highly proliferating tumour cells) would be increas-
ingly sensitive to proteasome inhibition compared to post-mitotic somatic cells. On the other hand, post-mitotic 
tissues (e.g. neuronal cells) would be likely increasingly sensitive to inhibitors suppressing both CT-L and C-L 
proteasomal activities and of course to ALP inhibition.
We sought to further verify our findings in the fly model, in human cancer cell lines and in peripheral blood 
mononuclear cells (PBMCs) and red blood cells (RBCs) isolated from MM patients prior and after therapeutic 
treatment with CFZ or BTZ. In accordance to our observations in flies, treatment of the MM JJN3 (Fig. 6A1) or 
the colon adenocarcinoma DLD-1 (Fig. 6A2) cells with BTZ or CFZ revealed an increased specificity of CFZ 
(compared to BTZ) against the CT-L proteasomal activity. Furthermore, we noted that PBMCs express higher 
basal proteasome activities as compared to RBCs (Fig. 6B1), and CFZ was increasingly selective (compared to 
BTZ) against CT-L in both PBMCs and RBCs (Fig. 6B2).
Taken together these data suggest that the CFZ superiority over BTZ on toxic effects likely relates to its 
increased selectivity for the CT-L proteasome activity.
Discussion
UPP is a key regulator of cellular proteostasis and thus a major regulatory hub for cellular survival in both phys-
iological and cancer cells. Thus, it is not surprising that the usage of proteasome inhibitors has revolutionised 
cancer therapy over the last two decades1,35. BTZ and CFZ have demonstrated clinical efficacy in the treatment 
of haematological cancers and are under evaluation for other malignancies36,37. Nonetheless, their therapeutic 
profile and demonstrated adverse effects in the clinic are dissimilar11. Herein, we have comparatively analysed 
the CFZ and BTZ effects in Drosophila flies and found that after oral administration they are not hydrolysed in 
flies’ tissues. Also, as in the clinic, under conditions of comparable CT-L inhibition, CFZ was less toxic as com-
pared to BTZ. These findings further validate the fly model as an in vivo experimental platform for screening the 
efficacy and/or safety of proteasome inhibitors and/or other drugs9,27. This notion is further supported by the 
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finding that the ratio of the different doses used to achieve similar rates of CT-L inhibition in Drosophila somatic 
tissues (i.e. 1 μM BTZ vs. 50 μM CFZ in culture medium) is reminiscent to the therapeutic doses used in the clinic 
(i.e. ~1.3 mg/m2 BTZ vs. ~25–50 mg/m2 CFZ).
Figure 4. Comparative short and long term effects of CFZ and BTZ to proteasome peptidases activity in flies’ 
somatic tissues. (A,B) Relative (%) CT-L (LLVY/β5), C-L (LLE/β1) and T-L (LRR/β2) proteasome activities, 
in flies’ somatic tissues following treatment with the indicated concentrations of CFZ or BTZ according to the 
protocol described in Supplementary Fig. S7A,B, respectively. In (A), flies were continuously exposed to the 
shown inhibitors and were transferred to fresh culture medium (containing –or not– the drug) every 4 days. 
A-F denotes time points (see also arrows in Supplementary Fig. S7A) of proteasome activities measurement 
as follows: A: Exposure for 1 day to the PI; B: exposure for 4 days [in the culture medium of (A)] to the PI; C: 
exposure for 5 days to the PI (1 day in fresh culture medium containing the PI); D: exposure for 8 days  
[4 days in the culture medium of (C)] to the PI; E: exposure for 9 days to the PI (1 day in fresh culture medium 
containing the PI); F: exposed for 12 days [4 days in the culture medium of (E)] to the PI. In (B), flies were 
exposed for a period of 72 hrs to the shown drugs and were then transferred to inhibitor-free culture medium. 
A-E indicates time points (see also arrows in Supplementary Fig. S7B) of proteasome activities measurement 
as follows: A: Exposure for 3 days to the shown PI; B: flies from (A) exposed for 1 day to inhibitor-free culture 
medium; C: flies from (A) exposed for 2 days to inhibitor-free culture medium; D: flies from (A) exposed 
for 3 days to inhibitor-free culture medium; and E: flies from (A) exposed for 4 days to inhibitor-free culture 
medium. (C) Relative (%) CT-L (LLVY/β5), C-L (LLE/β1) and T-L (LRR/β2) proteasome activities in dissected 
head and thorax preparations; CFZ or BTZ were administered to young flies at the shown doses for 13 days. PI, 
proteasome inhibitor; Con, indicates inhibitor-free culture medium. Bars, ±SD (n ≥ 2). *P < 0.05; **P < 0.01.
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Figure 5. Proteasome and lysosomal cathepsins enzymatic activities in adult flies’ tissues or developmental 
stages (ovaries and larvae) enriched in mitotic (ovaries and larvae) or post-mitotic (adult soma) cell lineages. 
(A) Relative (%) activity of the CT-L (LLVY/β5), C-L (LLE/β1) and T-L (LRR/β2) proteasome peptidases in 
adult somatic tissues, ovaries and larvae. (B) Relative (%) lysosomal cathepsins B, L activities in adult somatic 
tissues, ovaries and larvae. In all cases comparisons were vs. values (set to 100%) in adult somatic tissues. Bars, 
±SD (n ≥ 2). *P < 0.05; **P < 0.01.
Figure 6. CFZ is increasingly selective (compared to BTZ) for the CT-L proteasome activity in human cancer 
cell lines or in PBMCs/RBCs (PBMCs express higher proteasomal activities vs. RBCs) isolated from patients 
treated with therapeutic CFZ or BTZ. (A) Relative CT-L and C-L proteasomal activities in JJN3 (A1) and DLD-1 
(A2) tumour cell lines treated with the shown concentrations of BTZ or CFZ. Shown comparisons were vs. basal 
proteasomal activities in non-treated cells. (B1) Relative (%) basal activity of the CT-L (LLVY/β5), C-L (LLE/
β1) and T-L (LRR/β2) proteasome peptidases in isolated PBMCs and RBCs. (B2) Relative (%) CT-L, C-L and 
T-L proteasome activities in PBMCs and RBCs isolated from MM patients after receiving therapeutic doses 
of BTZ or CFZ for 24 hrs. In (B1) normalization was vs. values (set to 100%) in PBMCs; in (B2) normalization 
was vs. values before treatment. Samples in (B) were from both male and female donors. Bars, ±SD. *P < 0.05; 
**P < 0.01.
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Despite differences in the intensity of molecular responses, both CFZ and BTZ mobilised antioxidant and pro-
teostatic modules in a CncC/Nrf2 and, more importantly, age-dependent manner. In support, CFZ and BTZ have 
been previously implicated in ROS production and induction of Hsp7038,39. Also, these inhibitors likely activate 
prosurvival autophagy as can be assumed from upregulation of autophagic genes and of lysosomal cathepsins 
activity in flies’ tissues. Similarly, it was shown previously in mammalian cells40 that CFZ induced autophagy 
via induction of the Unfolded Protein Response. These findings broaden the potential means for increasing the 
therapeutic window against malignancies, e.g. by also using inhibitors of ALP or of the cytoprotective CncC/
Nrf2 pathway. Consistently, a recent study revealed that a combination therapy with CFZ plus Chloroquine (an 
ALP inhibitor) was highly effective in the treatment of MM in a mouse xenograft model41. Nevertheless, these 
therapeutic approaches should be applied with caution as according to our findings post mitotic cells appear 
to be increasingly dependent on ALP functionality42 and so there is an increased risk of serious toxic effects. 
Furthermore, our data raise the significant issues of, a. directly measuring (or even better adjusting) the levels of 
achieved reduction in targeted proteasomal activities after administration of therapeutic inhibitors and not just 
delivering drugs in mg/m2 doses and; b. considering the parameter of age during therapy, as it is anticipated that, 
due to age-dependent reduction in genomic responses, the toxicity of the inhibitors would likely increase in aged 
patients.
Our finding that CFZ did not significantly affect the climbing activity of flies indicates no significant patholo-
gies in Drosophila muscle, peripheral neurons or central nervous system. Moreover, CFZ did not exert significant 
effects during developmental stages, while, as compared to BTZ, its administration in adult flies promoted the 
increase of their mortality rate to a lesser extent. In support, administration of therapeutic doses of CFZ in MM 
patients is not associated with the development or significant worsening (if it follows BTZ treatment) of periph-
eral neuropathy14,22,43. Also, according to the ENDEAVOR study the number of patients who had grade 2 or 
higher peripheral neuropathy (grouped term) was significantly higher in the BTZ group than in the CFZ group44. 
Interestingly, according to our findings both inhibitors caused cardiotoxicity in the fly model. This effect was 
manifested by bradycardia and/or arrhythmia and likely relates to reduced mitochondria number, as well as well 
as to significant disruption of mitochondrial structure and respiration machineries functionality. In the clinic, 
CFZ has been related to a low but reproducible signal of cardiotoxicity, associated with reduction of ejection frac-
tion, which in most cases is reversible. Also, few studies have shown that CFZ and BTZ correlate with increased 
heart cytotoxicity and failure, respectively20,21,23,45. Moreover, in a primary neonatal rat myocytes model, exposure 
to BTZ or CFZ resulted in significant myocytes damage and induced apoptosis. Reportedly, the increased sensi-
tivity of myocytes to proteasome inhibitors was likely due to inhibition of the proteasomal-dependent sarcomeric 
protein turnover46. Cardiomyocytes are constantly bearing a hard mechanical work and increased metabolic 
rate, and are thus increasingly depended on functional mitochondria and UPP for their homeodynamic main-
tenance47. Therefore, it is not surprising that proteasome inhibition can lead to heart remodelling, dysfunction 
or even failure48,49. Nonetheless, further studies are needed in order to clarify in detail the role of UPP (and its 
therapeutic inhibitors) in heart function.
Our data indicate that the milder toxicity of CFZ in the fly model is likely due to selective inhibition of the 
CT-L proteasome activity; this finding was also verified in human cancer cell lines exposed to BTZ or CFZ, and 
in RBCs or PBMCs isolated from MM patients treated with BTZ or CFZ. In support, a C-L selective inhibitor 
(NC001) increased the CFZ mortality rate in the fly model. Therefore, considering the CFZ therapeutic effects, it 
seems that haematological tumours are uniquely sensitive to CT-L inhibition. In agreement with this notion, CFZ 
at a dose that selectively inhibits both the CT-L active sites of β5 and LMP7 induced an anti-tumour response in 
MM, non-Hodgkin lymphoma (NHL) and leukaemia cells with minimal cytotoxic effects in non-transformed 
cells50. Nevertheless, although the CT-L site seems to be rate limiting for protein breakdown15,51, inhibiting CT-L 
alone is rarely sufficient to block protein degradation19,52. Thus, co-inhibition of either the C-L or T-L sites is usu-
ally required to effectively inhibit protein breakdown19,52 and to increase the sensitivity of other types of cancer 
cells (e.g. solid tumours) to inhibitors of the CT-L site, including BTZ and CFZ53,54; it is nonetheless anticipated 
that this approach will significantly enhance the toxic effects of the used inhibitors.
Interestingly, we found that mitotic cells express higher (as compared to post-mitotic cell lineages) proteas-
ome activities, whereas post-mitotic cells are characterised by increased lysosomal cathepsins activity. It is thus 
logical to assume that highly proliferating tumour cells, would be addicted to high expression levels and activi-
ties of UPP10,55–57 (and thus differentially sensitive to its inhibition) due to enhanced protein synthesis and thus 
increased needs for protein synthesis quality control. On the other hand, post-mitotic tissues likely mostly depend 
on ALP for proteostasis maintenance and clearance of proteome damage42. This notion suggests that the adverse 
effects in post-mitotic tissues, e.g. nervous system, would be enhanced during therapeutic approaches which 
co-inhibit UPP and ALP in order to maximize anti-tumour therapy.
Taken together our data suggest that (Supplementary Fig. S10), compared to BTZ, administration of ther-
apeutic CFZ exerts milder degenerative effects (except cardiac toxicity) in flies’ tissues likely due to increased 
selectivity for the CT-L proteasomal activity. These findings provide a reasonable explanation for the differential 
adverse effects of CFZ and BTZ in the clinic.
Methods
Proteasome inhibitors. BTZ (Velcade®) was obtained commercially and CFZ was from Onyx 
Pharmaceuticals, Inc. (an Amgen subsidiary). The inhibitors were diluted in ddH2O; aliquoted and stored at 
−20 °C. Daily used aliquots were stored at 4 °C. For the in vivo assays inhibitors were added in the fly culture 
medium.
Fly Stocks. The Drosophila strains used in this study were the wild-type Oregon R and w1118 strains. The 
AREs (Antioxidant Response Elements)-GFP transgenic reporter line gstD-ARE:GFP/II (ARE-containing the 
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enhancer of the gstD1 gene) and the UAS cncCRNAi (overexpress an inverted repeat corresponding to the cncC/
nrf2 gene58) line, along with the Tubulin GeneSwitch Gal4 (tubGSGal4) driver were a gift from Prof. D. Bohmann 
(University of Rochester, NY, USA). The tubulin-GeneSwitch-Gal4 (tubGSGal4) flies express RU486-regulated 
Gal4 under the control of the tubulin enhancer; thus, the conditional driver (tubGSGal4) is ubiquitously activated 
upon dietary administration of RU486 (320 μM). The Gal4MEF2 muscle-specific driver and the MitoGFP reporter 
lines were a gift from Prof. A. Daga (University of Padua, Padova, Italy). As gonads display distinct regulation of 
proteostatic mechanisms and ageing rates compared to adult somatic tissues59, in all shown experiments (unless 
otherwise indicated) referring to adult flies only microdissected somatic tissues (head and thorax; equal numbers 
from mated male and female flies) were analysed.
Flies culture, exposure to compounds, locomotion and longevity assays. Flies stocks were main-
tained at 23 °C, 60% relative humidity on a 12-h light: 12-h dark cycle and were fed standard medium (unless oth-
erwise indicated)60. All used compounds, e.g. BTZ, CFZ or RU486 (Sigma-Aldrich, M8046) were added in flies’ 
culture medium. The duration of flies’ exposure to compounds and used doses are indicated in Figure legends.
Locomotion (climbing) and longevity assays were done as described previously9,59,61. For survival curves and 
statistical analyses the Kaplan-Meier procedure and log-Rank (Mantel-Cox) test were used; significance was 
accepted at P < 0.05. Statistical analyses of the lifespan experiments are presented in Supplementary Table S1.
Cell lines and culture conditions. The human myeloma JJN3 cell line was a gift from Prof. C. Mitsiades 
(Dana-Farber Cancer Institute, Harvard Medical School, USA) and the colon adenocarcinoma DLD-1 cell line 
was obtained from the American Tissue Culture Collection (ATCC®). JJN3 and DLD-1 cells were maintained 
in RPMI-1640 medium containing 10% (v/v) foetal bovine serum and 2 mM glutamine. Cells were cultured in 
a humidified incubator at 5% CO2 and 37 °C. DLD-1 cell line was subcultured using a trypsin/EDTA solution, 
while a saturated JJN3 (grown in suspension) cell culture was collected after centrifugation and splitted 1:3 to 1:6 
every 2-3 days62.
PBMCs and RBCs isolation. PBMCs and RBCs were collected by using Biocoll [density 1.077 g/ml 
(Biochrom)] from whole blood isolated from MM patients upon diagnosis or 24 hrs post-CFZ or BTZ adminis-
tration. Freshly collected heparinised blood was transferred into a 15 mL tube and was then diluted (1:1 dilution) 
with phosphate-buffered saline (PBS). The diluted whole blood was then carefully layered over the separation 
medium (1/2 x the volume of the sample); the two phases were kept separated before the centrifugation. Tubes 
were then centrifuged at 400 xg for 30 min at 20 °C (acceleration 9, braking rate 0). Both cell types were collected; 
washed with PBS and were then processed for proteasome peptidases activity measurement.
Full Methods, description of Statistical analyses and any associated References are available in Supplemental 
Methods.
Ethics approval and consent to participate. Informed consent was obtained from all individual partic-
ipants that were included in the study, which was conducted in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments 
or comparable ethical standards. An approval has been obtained from the Institutional Review Board/Scientific 
committee of Alexandra Hospital (Athens, Greece) for the collection of blood samples.
Data availability statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding authors on reasonable request.
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